COMPARATIVE EFFECTS OF FENOLDOPAM MESYLATE AND NITROPRUSSIDE ON LEFT-VENTRICULAR PERFORMANCE IN SEVERE SYSTEMIC HYPERTENSION

被引:11
作者
HACKMAN, BB [1 ]
GRIFFIN, B [1 ]
MILLS, M [1 ]
RAMANATHAN, KB [1 ]
机构
[1] UNIV TENNESSEE CTR HLTH SCI, DEPT MED, DIV CARDIOL, MEMPHIS, TN 38163 USA
关键词
D O I
10.1016/0002-9149(92)90793-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To compare the effects of fenoldopam (n = 15), a selective dopamine-1 agonist, and nitroprusside (n = 14) on left ventricular (LV) function in severely hypertensive subjects (diastolic blood pressure (BP) > 120 mm Hg), both agents were infused to reduce diastolic BP by 40 mm Hg (or < 110 mm Hg). Indexes of LV systolic and diastolic functions were obtained using gated radionuclide angiography before the initiation of treatment and after targeted BP was achieved. Both fenoldopam and nitroprusside effectively reduced systolic and diastolic BP to target levels. Changes in heart rate, peak filling rate and relative end-diastolic volume were similar with both agents. Baseline ejection fraction increased after infusion of both drugs. The magnitude of the increase in ejection fraction was far greater with fenoldopam than with nitroprusside (+22% vs +8%; p = 0.04), despite a lesser reduction in systolic BP (-12 vs -22%, p = 0.002). Furthermore, the reduction in relative end-systolic volume (-35 vs -20%; p = 0.04), and increase in the ratio of peak systolic pressure to relative end-systolic volume (+43 vs +6%; p = 0.007) were greater after fenoldopam than after nitroprusside. The greater increment in parameters of LV systolic function produced by fenoldopam than by nitroprusside suggests an effect on LV performance that is independent of afterload reduction.
引用
收藏
页码:918 / 922
页数:5
相关论文
共 32 条
[1]   THE EFFECT OF FENOLDOPAM, A DOPAMINERGIC AGONIST, ON RENAL HEMODYNAMICS [J].
ALLISON, NL ;
DUBB, JW ;
ZIEMNIAK, JA ;
ALEXANDER, F ;
STOTE, RM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (03) :282-288
[2]   COMPARATIVE ACUTE BLOOD-PRESSURE REDUCTION FROM INTRAVENOUS FENOLDOPAM MESYLATE VERSUS SODIUM-NITROPRUSSIDE IN SEVERE SYSTEMIC HYPERTENSION [J].
BEDNARCZYK, EM ;
WHITE, WB ;
MUNGER, MA ;
GONZALEZ, FM ;
PANACEK, EA ;
WEED, SG ;
RUTHERFORD, WF ;
NARA, AR ;
GREEN, JA .
AMERICAN JOURNAL OF CARDIOLOGY, 1989, 63 (13) :993-996
[3]   THE USES AND LIMITATIONS OF END-SYSTOLIC INDEXES OF LEFT-VENTRICULAR FUNCTION [J].
CARABELLO, BA ;
SPANN, JF .
CIRCULATION, 1984, 69 (05) :1058-1064
[4]   SELECTIVE PERIPHERAL DOPAMINE-1 RECEPTOR STIMULATION WITH FENOLDOPAM IN HUMAN ESSENTIAL-HYPERTENSION [J].
CAREY, RM ;
STOTE, RM ;
DUBB, JW ;
TOWNSEND, LH ;
ROSE, CE ;
KAISER, DL .
JOURNAL OF CLINICAL INVESTIGATION, 1984, 74 (06) :2198-2207
[5]   DRUGS 5 YEARS LATER - NITROPRUSSIDE [J].
COHN, JN ;
BURKE, LP .
ANNALS OF INTERNAL MEDICINE, 1979, 91 (05) :752-757
[6]   RENAL AND HEMODYNAMIC-EFFECTS OF INTRAVENOUS FENOLDOPAM VERSUS NITROPRUSSIDE IN SEVERE HYPERTENSION [J].
ELLIOTT, WJ ;
WEBER, RR ;
NELSON, KS ;
OLINER, CM ;
FUMO, MT ;
GRETLER, DD ;
MCCRAY, GR ;
MURPHY, MB .
CIRCULATION, 1990, 81 (03) :970-977
[7]  
GREEN J, 1987, CLIN PHARMACOL THER, V41, P242
[8]  
GUPTA PD, 1990, AM J CARDIOL, V66, P1118
[9]  
HAHN RA, 1982, J PHARMACOL EXP THER, V223, P305
[10]   CARVEDILOL FOR SYSTEMIC HYPERTENSION [J].
HEBER, ME ;
BRIGDEN, GS ;
CARUANA, MP ;
LAHIRI, A ;
RAFTERY, EB .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 59 (05) :400-405